Human EphA2 (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.
Cat #
Size
Price
Quantity
814401
25 ug
$145
814402
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
EphA2
Species
Human
Sources
Recombinant Human EphA2 (Gln25-Asn534) with C-terminus His-tag is expressed in CHO cell.
accession number
P29317
Molecular Weight
The protein has a predicted molecular weight of 57.7 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE.
Affinity Tag
C-His
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
EphA2 (Ephrin type-A receptor 2) is a receptor tyrosine kinase involved in cell adhesion, migration, and tissue organization. It plays a critical role in embryonic development and angiogenesis. EphA2 is frequently overexpressed in various cancers, including breast, lung, and prostate cancer. Overexpression is associated with increased tumor growth, invasiveness, and poor clinical outcomes. Because of its role in promoting tumor progression, EphA2 is being actively explored as a therapeutic target in oncology. Therapeutic strategies include monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates targeting EphA2-positive tumors.
Human EphA2 (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.
